Well those at the meeting were told that all the data except some "marker" data will be presented. This is a direct statement from MM that the cell-associated data will be released.
You do realise that if the cell-associated data is still being analysed and the free virus in the blood was below the detection limit of the assay they used that BIT right now has zero evidence that BIT225 is having any direct effect on HIV viral loads in patients? I will go out on a limb (a very short one) and say all we will get next week is some reduction in the sCD163 levels and maybe some sign of T-cell activation. If this is all BIT has it is going to be a long northern winter for their pharma partnership campaign.
BIT Price at posting:
17.0¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)